ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal

0:00-1:57

In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.

Publisher

Applied Clinical Trials

Link

audioboom.com/posts/8972833

Published

November 4, 2026

Duration

2 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

AC

Applied Clinical Trials

@appliedclinicaltrials

#communityresearchfinancing #neuroscienceendpointdata #tevasbiosimilardeal #lifesciences

The Nile